Publicaciones científicas

Helper-dependent adenovirus achieve more efficient and persistent liver transgene expression in non-human primates under immunosuppression

Unzu C(1), Melero I(2), Hervás-Stubbs S(3), Sampedro A(1), Mancheño U(1), Morales-Kastresana A(1), Serrano-Mendioroz I(1), de Salamanca RE(4), Benito A(5), Fontanellas A(6).
(1) Immunotherapy and Hepatology Area, Centre for Applied Medical Research (CIMA), University of Navarra, Spain.
(2) [1] Immunotherapy and Hepatology Area, Centre for Applied Medical Research (CIMA), University of Navarra, Spain [2] Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain [3] Department of Oncology, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Spain.
(3) [1] Immunotherapy and Hepatology Area, Centre for Applied Medical Research (CIMA), University of Navarra, Spain [2] Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
(4) Research Center, Hospital Universitario 12 de Octubre, University Complutense of Madrid, Spain.
(5) [1] Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain [2] Department of Radiology, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Spain.
(6) [1] Immunotherapy and Hepatology Area, Centre for Applied Medical Research (CIMA), University of Navarra, Spain [2] Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain [3] CIBERehd, University Clinic Navarra. Instituto de Salud Carlos III. Pamplona, Spain.

Revista: Gene Therapy

Fecha: 30/06/2015

Oncología Médica Radiología

Resumen

Helper-dependent adenoviral (HDA) vectors constitute excellent gene-therapy tools for metabolic liver diseases. We have previously shown that an HDA vector encoding human porphobilinogen deaminase (PBGD) corrects acute intermittent porphyria mice.

Now, six non-human primates were injected in the left hepatic lobe with the PBGD-encoding HDA vector to study levels and persistence of transgene expression. Intrahepatic administration of 5 × 1012 viral particles/kg (1010 infective units/kg) of HDA only resulted in transient (≈14 weeks) transgene-expression in one out of three individuals.

In contrast, a more prolonged 90-day immunosuppressive regimen (tacrolimus, mycophenolate, rituximab and steroids) extended meaningful transgene expression for over 76 weeks in two out of two cases. Transgene-expression under immunosuppression reached maximum levels 6 weeks after HDA administration and gradually declined reaching a stable plateau within the therapeutic range for acute porphyria. The non-injected liver lobes also expressed the transgene because of vector circulation. Immunosuppression controlled anti-capsid T-cell responses and decreased the induction of neutralizing antibodies. Re-administration of HDA-hPBGD at week +78 achieved therapeutically meaningful transgene-expression only in those animals receiving immunosuppression again at the time of this second vector exposure.

Overall, immunity against adenoviral capsids poses serious hurdles for long-term HDA-mediated liver transduction, which can be partially circumvented by pharmacological immunosuppression.Gene Therapy accepted article preview online, 30 June 2015. doi:10.1038/gt.2015.64.

CITA DEL ARTÍCULO  Gene Ther. 2015 Jun 30. doi: 10.1038/gt.2015.64.

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra